Analyst consensus rating
Aclaris Therapeutics Analyst Rating: none
ACRS is rated none by 10 analysts with a $10.20 target. As of 2026-08-27.
Direct answer
Aclaris Therapeutics's consensus rating is none.
10 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $10.20.
Forecast evidence checked August 27, 2026.
Get free Aclaris Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $6.19
- Average price target
- $10.20
- High price target
- $16.00
- Low price target
- $4.00
- Low target gap
- -35.4%
- Target upside
- +64.8%
- High target gap
- +158.5%
- Target range width
- 193.9%
- Consensus rating
- none
- Analysts
- 10
- Evidence date
- August 27, 2026
- Valid through
- September 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Aclaris Therapeutics?
Aclaris Therapeutics has a verified none consensus. The same dataset has an average price target of $10.20.
How far are Aclaris Therapeutics's low and high targets from the recorded price?
The low target implies -35.4%, while the high target implies +158.5%.
How many analysts are included in Aclaris Therapeutics's consensus?
The verified consensus includes 10 analysts.
How is Aclaris Therapeutics's target upside or downside calculated?
The average target of $10.20 is divided by the recorded price of $6.19, then one is subtracted to produce +64.8%. This does not guarantee a future return.
When was Aclaris Therapeutics's analyst forecast verified?
The data was verified on 2026-08-27. The dataset is valid through 2026-09-03.